112 related articles for article (PubMed ID: 36239561)
41. The utility of TTF-1, napsin A, CK5 and p63 staining in the sub-classification of non-small cell carcinoma of the lung.
van Zyl A; Schubert PT; Koegelenberg CFN
Cytopathology; 2019 Nov; 30(6):586-591. PubMed ID: 31206846
[TBL] [Abstract][Full Text] [Related]
42. Genotype-phenotype correlation in Chinese patients with pulmonary mixed type adenocarcinoma: Relationship between histologic subtypes, TITF-1/SP-A expressions and EGFR mutations.
Jie-Liu ; Li XY; Zhao YQ; Liu RQ; Zhang JB; Ma J; Chen LJ; Hu XF
Pathol Res Pract; 2014 Mar; 210(3):176-81. PubMed ID: 24370340
[TBL] [Abstract][Full Text] [Related]
43. EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect.
Sahnane N; Frattini M; Bernasconi B; Zappa F; Schiavone G; Wannesson L; Antonelli P; Balzarini P; Sessa F; Mazzucchelli L; Tibiletti MG; Martin V
Clin Lung Cancer; 2016 Jan; 17(1):56-61. PubMed ID: 26381283
[TBL] [Abstract][Full Text] [Related]
44. Clinicopathological and prognostic features of surgically resected pathological stage I lung adenocarcinoma harboring epidermal growth factor receptor and K-ras mutation.
Kaseda K; Asakura K; Kazama A; Ozawa Y
Thorac Cancer; 2017 May; 8(3):229-237. PubMed ID: 28322512
[TBL] [Abstract][Full Text] [Related]
45. High prevalence of ROS1 gene rearrangement detected by FISH in EGFR and ALK negative lung adenocarcinoma.
Xu Y; Chang H; Wu L; Zhang X; Zhang L; Zhang J; Li Y; Shen L; Zhu X; Zhou X; Bai Q
Exp Mol Pathol; 2020 Dec; 117():104548. PubMed ID: 32979347
[TBL] [Abstract][Full Text] [Related]
46. Dual color multiplex TTF-1 + Napsin A and p63 + CK5 immunostaining for subcategorizing of poorly differentiated pulmonary non-small carcinomas into adenocarcinoma and squamous cell carcinoma in fine needle aspiration specimens.
Sethi S; Geng L; Shidham VB; Archuletta P; Bandyophadhyay S; Feng J; Madan S; Shi D; Tranchida P; Giorgadze T
Cytojournal; 2012; 9():10. PubMed ID: 22582081
[TBL] [Abstract][Full Text] [Related]
47. ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare.
Zhao W; Choi YL; Song JY; Zhu Y; Xu Q; Zhang F; Jiang L; Cheng J; Zheng G; Mao M
Lung Cancer; 2016 Apr; 94():22-7. PubMed ID: 26973202
[TBL] [Abstract][Full Text] [Related]
48. Analysis of clinical characteristics and differential diagnosis of the lung biopsy specimens in 99 adenocarcinoma cases and 111 squamous cell carcinoma cases: utility of an immunohistochemical panel containing CK5/6, CK34βE12, p63, CK7 and TTF-1.
Xu XY; Yang GY; Yang JH; Li J
Pathol Res Pract; 2014 Oct; 210(10):680-5. PubMed ID: 25063315
[TBL] [Abstract][Full Text] [Related]
49. Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma.
Sun JM; Lira M; Pandya K; Choi YL; Ahn JS; Mao M; Han J; Park K; Ahn MJ; Kim J
Lung Cancer; 2014 Feb; 83(2):259-64. PubMed ID: 24300132
[TBL] [Abstract][Full Text] [Related]
50. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes.
Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
Eur J Cancer; 2014 May; 50(7):1361-9. PubMed ID: 24548766
[TBL] [Abstract][Full Text] [Related]
51. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.
de Melo AC; Karen de Sá V; Sternberg C; Olivieri ER; Werneck da Cunha I; Fabro AT; Carraro DM; de Barros e Silva MJ; Pimenta Inada HK; de Mello ES; Soares FA; Takagaki T; Ferreira CG; Capelozzi VL
Oncology; 2015; 89(3):175-86. PubMed ID: 25833149
[TBL] [Abstract][Full Text] [Related]
52. Clinical and the prognostic characteristics of lung adenocarcinoma patients with ROS1 fusion in comparison with other driver mutations in East Asian populations.
Chen YF; Hsieh MS; Wu SG; Chang YL; Shih JY; Liu YN; Tsai MF; Tsai TH; Yu CJ; Yang JC; Yang PC
J Thorac Oncol; 2014 Aug; 9(8):1171-9. PubMed ID: 25157770
[TBL] [Abstract][Full Text] [Related]
53. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
Kim HR; Lim SM; Kim HJ; Hwang SK; Park JK; Shin E; Bae MK; Ou SH; Wang J; Jewell SS; Kang DR; Soo RA; Haack H; Kim JH; Shim HS; Cho BC
Ann Oncol; 2013 Sep; 24(9):2364-70. PubMed ID: 23788756
[TBL] [Abstract][Full Text] [Related]
54. Prognostic Impact of Intra-alveolar Tumor Spread in Pulmonary Adenocarcinoma.
Warth A; Muley T; Kossakowski CA; Goeppert B; Schirmacher P; Dienemann H; Weichert W
Am J Surg Pathol; 2015 Jun; 39(6):793-801. PubMed ID: 25723114
[TBL] [Abstract][Full Text] [Related]
55. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
[TBL] [Abstract][Full Text] [Related]
56. Comprehensive analysis of the clinicopathological features, targetable profile, and prognosis of mucinous adenocarcinoma of the lung.
Ueda D; Ito M; Tsutani Y; Giménez-Capitán A; Román-Lladó R; Pérez-Rosado A; Aguado C; Kushitani K; Miyata Y; Arihiro K; Molina-Vila MA; Rosell R; Takeshima Y; Okada M
J Cancer Res Clin Oncol; 2021 Dec; 147(12):3709-3718. PubMed ID: 33796913
[TBL] [Abstract][Full Text] [Related]
57. Clinical relevance of PD-L2 expression in surgically resected lung adenocarcinoma.
Takamochi K; Hara K; Hayashi T; Kohsaka S; Takahashi F; Suehara Y; Shimokawa M; Suzuki K
Lung Cancer; 2022 Jun; 168():50-58. PubMed ID: 35489160
[TBL] [Abstract][Full Text] [Related]
58. [Clinicopathological and prognostic significance of a panel of tumor biomarkers in lung adenocarcinoma: a tissue microarray study].
Yang X; Xue L; Guo L; Wen P; Lin D
Zhongguo Fei Ai Za Zhi; 2014 Mar; 17(3):243-53. PubMed ID: 24667263
[TBL] [Abstract][Full Text] [Related]
59. Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.
Chen YF; Hsieh MS; Wu SG; Chang YL; Yu CJ; Yang JC; Yang PC; Shih JY
J Thorac Oncol; 2016 Jul; 11(7):1140-52. PubMed ID: 27094798
[TBL] [Abstract][Full Text] [Related]
60. Tumor Spread through Air Spaces Affects the Recurrence and Overall Survival in Patients with Lung Adenocarcinoma >2 to 3 cm.
Dai C; Xie H; Su H; She Y; Zhu E; Fan Z; Zhou F; Ren Y; Xie D; Zheng H; Kadeer X; Chen D; Zhang L; Jiang G; Wu C; Chen C
J Thorac Oncol; 2017 Jul; 12(7):1052-1060. PubMed ID: 28389373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
